Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination

Fewer than half of children with high-risk neuroblastoma survive. Many of these tumors harbor high-level amplification of MYCN, which correlates with poor disease outcome. Using data from our large drug screen we predicted, and subsequently demonstrated, that MYCN-amplified neuroblastomas are sensit...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer cell 2016-02, Vol.29 (2), p.159-172
Hauptverfasser:	Ham, Jungoh, Costa, Carlotta, Sano, Renata, Lochmann, Timothy L., Sennott, Erin M., Patel, Neha U., Dastur, Anahita, Gomez-Caraballo, Maria, Krytska, Kateryna, Hata, Aaron N., Floros, Konstantinos V., Hughes, Mark T., Jakubik, Charles T., Heisey, Daniel A.R., Ferrell, Justin T., Bristol, Molly L., March, Ryan J., Yates, Craig, Hicks, Mark A., Nakajima, Wataru, Gowda, Madhu, Windle, Brad E., Dozmorov, Mikhail G., Garnett, Mathew J., McDermott, Ultan, Harada, Hisashi, Taylor, Shirley M., Morgan, Iain M., Benes, Cyril H., Engelman, Jeffrey A., Mossé, Yael P., Faber, Anthony C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aniline Compounds - therapeutic use Antineoplastic Agents - therapeutic use Apoptosis - genetics Cell Line, Tumor Humans N-Myc Proto-Oncogene Protein Neuroblastoma - drug therapy Neuroblastoma - genetics Neuroblastoma - pathology Nuclear Proteins Oncogene Proteins Sulfonamides - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!